fbpx

Stay Informed. Stay Competitive. Get Free Email Updates Dow 30 & Emerging Growth

Stay Informed. Stay Competitive.

Get Free Updates

Dow 30 & Emerging Growth

INM

InMed Pharmaceuticals, Inc.

  ( )

Page Views : 41727

Analyst Ratings

 
Buy
Strong Buy
0%
Buy
100%
Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

vista's key points

  • InMed Pharmaceuticals is a global leader in the development, manufacturing and commercialization of rare cannabinoids for Pharmaceutical industry and the Consumer Health & Wellness Industry.
  • With the closing of The BayMedica Acquisition, InMed now has unparalleled cannabinoid manufacturing capabilities to serve a spectrum of consumer markets, including pharmaceutical and health and wellness and is generating revenue.
  • InMed is developing a diverse pipeline of rare cannabinoid therapeutics across a spectrum of diseases with high unmet medical needs - currently focused on epidermolysis bullosa (“EB”) and glaucoma while actively seeking to add development programs for additional indications.
  • InMed's lead product, INM-755 (cannabinol) cream, is under development in a Phase 2 Clinical Trial for the treatment of epidermolysis bullosa (“EB”), a severe genetic skin disorder, which affects approximately 50,000 patients in North America, Europe, & Japan.
  • InMed's INM-088 product is in preclinical development for the treatment of glaucoma, the second leading cause of blindness in the developed world.
  • InMed's continued optimization of IntegraSyn™ has increased the cannabinoid yield to a level of 5 g/L, further improving the economics of this proprietary manufacturing approach of rare cannabinoids in advance of large-scale production, which exceeds currently reported industry yields.
  • InMed's IntegraSyn provides a cost effective approach for the manufacturing of rare cannabinoid API’s for the pharmaceutical industry.
  • InMed improved their cash position on July 2nd as it closed a private placement with an institutional investor for net proceeds of approximately $11 million
  • Analysts at HC Wainwright, Roth Capital Partners, & Edison Updated or Initiated Coverage on InMed in November, 2021 with 'BUY Recommendations', which included Price Targets ranging from $6-$20.53.

vista's key points

  • InMed Pharmaceuticals is a global leader in the development, manufacturing and commercialization of rare cannabinoids for Pharmaceutical industry and the Consumer Health & Wellness Industry.
  • With the closing of The BayMedica Acquisition, InMed now has unparalleled cannabinoid manufacturing capabilities to serve a spectrum of consumer markets, including pharmaceutical and health and wellness and is generating revenue.
  • InMed is developing a diverse pipeline of rare cannabinoid therapeutics across a spectrum of diseases with high unmet medical needs - currently focused on epidermolysis bullosa (“EB”) and glaucoma while actively seeking to add development programs for additional indications.
  • InMed's lead product, INM-755 (cannabinol) cream, is under development in a Phase 2 Clinical Trial for the treatment of epidermolysis bullosa (“EB”), a severe genetic skin disorder, which affects approximately 50,000 patients in North America, Europe, & Japan.
  • InMed's INM-088 product is in preclinical development for the treatment of glaucoma, the second leading cause of blindness in the developed world.
  • InMed's continued optimization of IntegraSyn™ has increased the cannabinoid yield to a level of 5 g/L, further improving the economics of this proprietary manufacturing approach of rare cannabinoids in advance of large-scale production, which exceeds currently reported industry yields.
  • InMed's IntegraSyn provides a cost effective approach for the manufacturing of rare cannabinoid API’s for the pharmaceutical industry.
  • InMed improved their cash position on July 2nd as it closed a private placement with an institutional investor for net proceeds of approximately $11 million
  • Analysts at HC Wainwright, Roth Capital Partners, & Edison Updated or Initiated Coverage on InMed in November, 2021 with 'BUY Recommendations', which included Price Targets ranging from $6-$20.53.

company profile

 

vista's view

InMed Pharmaceuticals (“InMed”) is a publicly traded company on the Nasdaq that trades under the symbol INM. InMed Pharmaceuticals is a global leader in the development, manufacturing and commercialization of rare cannabinoids for Pharmaceutical Industry and the Consumer Health & Wellness Industry. InMed is developing a cannabinoid synthesis manufacturing system...

Read More

vp watchlist

The VP Watchlist contains current coverage companies that deserve consideration for short term and long term portfolio additions.

Interviews

    Coming Soon

Stay Informed. Stay Competitive with FREE Insights on the Stock Market, Dow 30 & Emerging Opportunities.

Get Free Email Updates